Rituximab, lenalidomide, and ibrutinib in relapsed/refractory primary cutaneous diffuse large B-cell lymphoma, leg type

Br J Haematol. 2022 Feb;196(4):e30-e33. doi: 10.1111/bjh.17886. Epub 2021 Oct 12.

Authors

Donald C Moore¹, Amy C Soni¹, Bei Hu¹, Elton T Smith², Jonathan Levine¹, Tamara K Moyo¹, Ryan Jacobs¹, Nilanjan Ghosh¹, Steven I Park¹

Affiliations

¹ Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.
² Carolinas Pathology Group, Atrium Health, Charlotte, NC, USA.

PMID: 34642938
DOI: 10.1111/bjh.17886

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adenine / analogs & derivatives*
Adenine / pharmacology
Adenine / therapeutic use
Aged
Antineoplastic Combined Chemotherapy Protocols / pharmacology
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Humans
Leg / pathology*
Lenalidomide / pharmacology
Lenalidomide / therapeutic use*
Lymphoma, Large B-Cell, Diffuse / drug therapy*
Male
Middle Aged
Piperidines / pharmacology
Piperidines / therapeutic use*
Rituximab / pharmacology
Rituximab / therapeutic use*

Substances

Piperidines
ibrutinib
Rituximab
Lenalidomide
Adenine